Articles tagged with Tumor Cells
Researchers have identified a potential new target for anticancer therapeutics by showing that well-oxygenated tumor cells use lactate as a fuel, while hypoxic cells use glucose. Inhibiting this protein MCT1 disrupts the symbiotic relationship between the two cell types, leading to decreased tumor growth in mouse models.
Researchers found lactic acid is an important energy source for tumor cells and discovered a way to destroy hard-to-kill cells by preventing lactate delivery. Blocking lactate transport kills oxygenated cells that starve hypoxic cells, offering a novel approach to treating tumors.
A team of researchers at Cold Spring Harbor Laboratory has discovered 13 new tumor-suppressor genes in liver cancer, which can help improve diagnosis and treatment. The study used a powerful genetic screen to validate the functional contributions of these genes in living animals.
A study by UNC researchers found that palladin, a protein expressed mostly in invasive breast cancer cells, plays a crucial role in their ability to migrate and spread. Knocking down palladin expression reduced the ability of breast cancer cells to metastasize.
A recent study discovered that the Overexpressed in Lung Cancer 1 (OLC1) gene is consistently expressed at high levels in most lung cancers, particularly in smokers. OLC1 overexpression was also shown to induce tumor formation in tissue culture cells and mouse models of lung cancer.
Researchers from Universite de Montreal and Maisonneuve-Rosemont Hospital discovered a new biochemical pathway controlling DNA repair, which may lead to improved cancer treatment. The ATR protein plays a key role in this process, and its deficiency is often found in tumour cells.
Researchers at Baylor College of Medicine have developed a new treatment approach for neuroblastoma using T-lymphocytes with an artificial receptor that targets cancer cells. The treatment showed promise in early clinical trials, with one patient achieving complete remission and others experiencing stable disease for over a year.
Researchers develop a novel designer molecule that targets malignant melanoma cells using two different routes: triggering the immune system to attack and switching off a specific gene, driving cancer cells to suicide. Initial experiments in mouse models show significant inhibition of metastasis growth and tumor shrinkage.
Researchers identified a molecular reason why MEK inhibitors are limited in their ability to kill B-RAF mutant tumor cells, suggesting a new antitumor approach. MicroRNA15a modulates the expression of Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
Researchers have identified a new combination therapy that targets tumors with B-RAF mutations by combining MEK inhibitors with BH3 mimetics, showing promise in treating melanomas and other solid tumors.
Researchers identified a molecular mechanism involved in the development of cancer stem cells, which can lead to malignant brain tumors. Targeting this signaling pathway with gene therapy may prevent tumor recurrence.
A new study published in the Proceedings of the National Academy of Sciences found that apigenin, a naturally occurring compound in fruits and vegetables, improves cancer cells' response to chemotherapy. By localizing tumor suppressor p53 in the cell nucleus, apigenin facilitates cell death and stops tumor growth.
Researchers create customizable biological computer using synthetic RNA that can detect tumor cells and respond to biochemical signals. The device has potential medical applications, including targeted gene therapies and cancer treatment.
Researchers have found that Hodgkin lymphoma cells produce the cytokine IL-21, which helps them evade immune system detection. This discovery could lead to new therapy strategies for the disease, including blocking IL-21 production.
Researchers have found a new technique to quickly and reversibly fine-tune protein activity in cells and living mammals, providing a powerful tool for identifying protein functions. The technique involves pairing specially engineered proteins with the drug Shield-1, which prevents their degradation.
Researchers found erlotinib to effectively block EGFR, improving survival in patients with pancreatic cancer. In vitro studies revealed erlotinib's ability to repress cell growth, induce apoptosis, and suppress angiogenesis.
Researchers at the University of Pittsburgh have found that a virus, Merkel cell polyomavirus (MCV), is the cause of Merkel cell carcinoma, an aggressive form of skin cancer. The virus infects normal cells before they turn into cancer cells, and its replication can lead to the death of cancer cells.
A new advance in cellular imaging allows scientists to track the movement of live cells in the area around tumors, providing insights into how certain immune cells help or hinder tumor growth. This study sheds light on potential drug targets and mechanisms to enhance the body's natural immune response to cancer.
A team of Fox Chase researchers has identified a single genetic mutation as a key factor in the development of colorectal cancer. By studying individuals with a inherited 'one-hit' gene mutation, they discovered molecular changes that signal cancer presence and potential targets for preventive drugs.
A new study reveals that tumor blood vessel cells have the potential to differentiate into cartilage- or bone-like tissues, making them remarkably atypical. The research also found that these cells can undergo calcification, a process that may facilitate metastasis and tumor cell entry into the bloodstream.
University of Alabama at Birmingham researchers have developed a gene therapy virus to target ovarian cancer cells. The adenovirus-based approach has shown anti-tumor effects that appear safe for most patients, according to Drs. David T. Curiel and Ronald Alvarez.
Researchers at Ecole Polytechnique Fédérale de Lausanne and University of Pennsylvania School of Medicine have identified a protein called Hsp104 that dramatically reduces alpha-synuclein aggregation and dopaminergic degeneration in a rat model of Parkinson's disease. The study suggests that Hsp104 could be considered as a potential st...
Researchers at Duke University Medical Center have identified two types of cells in the brain that can give rise to medulloblastoma, a type of brain tumor. The study provides critical insight into how cancers develop and may help develop more rational and effective approaches to treatment.
Researchers have developed a novel method to kill tumor cells using nanoparticles and light. The technique employs quantum dots that emit light when exposed to megavoltage x-rays, which triggers the cancer-killing activity of Photofrin. This approach could be more effective in treating deeply seated tumors than current methods.
Researchers have developed a novel therapy that utilizes magnetic nanoparticles to target and capture cancer cells, which can then be removed from the body. This technology shows promise in treating ovarian cancer, where free-floating cancer cells spread throughout the abdominal cavity.
Researchers at Stanford University School of Medicine found that lowering levels of signaling molecule Myc to a specific threshold reverses cancer cell growth and returns tumor cells to their normal state. This breakthrough could lead to more effective cancer chemotherapy with fewer side effects for healthy cells.
Researchers at German Cancer Research Center discovered that tumor cells degrade HIPK2 to prevent programmed cell death. Blocking this degradation may increase effectiveness of radiotherapy or chemotherapy. The study suggests a new approach to cancer treatment by targeting the Siah-1 enzyme.
The Damon Runyon Cancer Research Foundation has awarded $2.25M to five outstanding young clinical investigators, including Dr. Ronald Buckanovich, Andrew Chan, Rachael Clark, Vassiliki Karantza-Wadsworth, and Elahe Mostaghel, to support their cancer research programs.
Researchers at the University of Missouri have developed a new non-toxic treatment that targets both tumor cells and blood vessels, effectively reducing breast cancer cell growth. The combination of PRIMA-1 and 2aG4 has been shown to improve responses and reduce side effects in pre-clinical trials.
Researchers at MIT discovered a new compound, cDPCP, that targets colorectal cells more effectively than oxaliplatin, potentially sparing other body tissues from damage. The study found that cDPCP requires the assistance of organic cation transporters to enter cells.
Researchers use monoclonal antibodies attached to carbon nanotubes that heat up when exposed to near-infrared light, killing cancer cells. The technique shows promise for targeting specific sites on lymphoma cells and potentially delivering a deadly payload.
A synthetic cocoa chemical slowed growth and accelerated destruction of human tumors in laboratory studies, suggesting it may be used for cancer chemoprevention or treatment. The strongest response was seen in colon cancer cells, with growth cut in half and most tumor cells damaged.
Researchers at CSHL confirm DLC1 as a tumor suppressor gene that, when deleted or inactivated, leads to liver cancer. The team also identifies RhoA as a key signaling intermediary required for tumor formation, paving the way for new therapeutic targets.
Researchers at Weill Cornell discovered that cancer stem cells without the protein CD133 can initiate metastatic disease, leading to more aggressive tumors. This finding opens up new avenues of investigation and redirects cancer research.
Researchers have created the smallest magnetic nanoparticles to date that can be used to locate cancer cells during MRI scans. The particles are about 8.4 nanometers in size and emit a stronger signal for detection, making them ideal for detecting tumors without surgery.
A recent study has cast doubt on CD133's status as a colon cancer stem cell marker, finding that the protein is expressed by most cells in colon tumors, not just stem cells. Both CD133+ and CD133- cells can initiate tumors when transplanted into mice.
Researchers found that overexpressed midkine (MK) and its truncated form (tMK) significantly promote the proliferation of gastric adenocarcinoma cells and tumor growth in nude mice. This study suggests tMK as a promising therapeutic target for gastric cancer treatment.
New study identifies IKK(beta) protein as key driver of pro-tumor switch in macrophages, which halts production of anti-tumor genes. Inactivating IKK(beta) reprograms macrophages into tumor killers, attracting professional immune cells to shrink tumors.
A study led by Beth Israel Deaconess Medical Center finds that a tumor suppressor protein called PML enables leukemia-initiating cells to maintain quiescence, making them resistant to conventional therapies. Inhibiting PML with an arsenic-based agent successfully treats chronic myeloid leukemia when combined with chemotherapy.
Researchers discover that myoepithelial cells play a critical role in regulating breast tumor progression and can act as 'gatekeepers' for the transition from in situ to invasive carcinoma. Understanding their pathways may open new avenues for cancer therapy and prevention.
A new study led by Dana-Farber Cancer Institute researchers found that abnormal surrounding cells cause the walls of the ducts to deteriorate, enabling tumor cells to escape. The discovery may lead to screening tests and treatments targeting genetic abnormalities in cells lining the ducts.
Researchers found that tumor cells can become resistant to radiation by jamming their self-destruct mechanisms, which could lead to improved cancer treatments. The study suggests that controlling the blocking-unblocking mechanism of DNA sequences involved in cell death may be key to making cancer cells sensitive to radiation again.
A new mechanism of how tumour cells communicate has been discovered, involving the release of vesicles called oncosomes containing cancer-causing proteins. This finding could lead to major clinical innovations and potentially serve as a clinical marker for cancer diagnosis.
Researchers have identified and cloned ovarian cancer stem cells, which may be the source of recurrence and resistance to chemotherapy. These stem cells can replicate indefinitely and are highly resistant to conventional treatment.
Researchers have discovered how HDAC inhibitors specifically damage cancer cells, leading to cell death. The compounds may also cause DNA damage that cannot be repaired, resulting in tumor cell death. However, these inhibitors can also have adverse effects, such as liver damage and metabolic abnormalities.
Researchers have identified a crucial role for antibodies in protecting against nontyphoidal strains of Salmonella bacteria, which causes fatal infections in African children. Meanwhile, a study on HOXB4 gene therapy found that early precursors can cause leukemia in large animals, highlighting the need for extreme caution in human trials.
Researchers discover that the Warburg effect, a unique metabolic process in cancer cells, is essential for tumor growth. The M2 form of pyruvate kinase (PKM2) plays a critical role in this process, enabling cancer cells to rapidly proliferate and produce energy through anaerobic glycolysis.
Researchers found that autophagy protects tumor cells from radiation and chemotherapy, making them more resistant to treatment. Blocking the recycling process could make these aggressive cancer cells more sensitive to therapies.
A University of Florida study found that the protein Bc12 blocks DNA repair in lung cancer cells, allowing them to thrive despite damage from radiation or chemicals. The discovery provides a new understanding of how lung cancer cells evade treatments, offering potential targets for drug development.
A new study shows that tumor blood vessels develop from precancerous stem cells, a type of cell that can become malignant. The findings suggest that screening anti-angiogenic drugs should include these cells to improve their effectiveness in blocking tumor growth.
Researchers developed gene therapy approach that attracts and 'trains' immune system cells to destroy deadly brain cancer cells, promoting long-term immunity and restoring normal brain function. The therapy shows promise as a potential treatment for glioblastoma multiforme, the most common and deadly type of brain cancer.
Immune cells can detect prostate cancer using a specific receptor on T cells, which recognizes the cancerous tumor. The molecular signpost is histone H4, a protein found in all cells but displayed only on the surface of tumor cells.
Scientists discovered that metastatic pancreatic cancer cells produce enough of the protein IDO to evade detection by the immune system, allowing them to spread in the body. This finding may lead to new ways to detect pancreatic cancer spreading to lymph nodes and enhance tumor immune therapy strategies.
Researchers studied yeast cells to understand actin network regulation, which is crucial for cell movement. The study found that Arp2/3 regulatory proteins have distinct roles in actin assembly and endocytosis, shedding light on the immune system's ability to target disease-causing invaders and cancer cells' migration.
Researchers developed a novel approach to gauge disease progress in adult T-cell lymphoma and leukemia, using firefly genes to detect cancer cells. The study found that combining PS-341 and zoledronic acid effectively killed 95% of ATLL cells, while also reducing bone resorption and calcium buildup.
Researchers designed a technique that uses the body's own cells and a virus to destroy cancer cells, which could lead to a new cancer vaccine. The study shows promising results in treating melanoma, lung cancer, and colorectal cancer by targeting tumor cells in the lymph nodes.
Researchers at CSHL have identified and repressed breast cancer stem cells in mouse tissue by manipulating microRNAs, suggesting a potential therapeutic target for breast cancer treatment. The study found that the delivery of the microRNA let-7 to breast-tissue cells can help distinguish stem-like tumor-initiating cells from other cells.
Researchers found that bortezomib selectively inhibits melanoma tumor cells by overactivating the cancer-promoting gene c-MYC, leading to increased production of NOXA and promoting cell death. The study suggests a novel treatment strategy for various types of cancer.
Researchers at Ohio State University have found that stress hormone norepinephrine promotes tumor cell growth and metastasis in certain types of blood cancer. The study suggests that blocking norepinephrine receptors may slow disease progression and improve treatment outcomes.
New compounds that target Inhibitor-of-Apoptosis (IAP) proteins have been shown to induce apoptosis in tumor cells. The IAP antagonists block the anti-death proteins and engage other players that lead to cell death, with little effect on healthy cells.